Tag: Health Care

Displaying 661 - 680 of 1054 results.

Pages

Protecting competition and consumers, the Federal Trade Commission today announced it is challenging Rite Aid Corporation’s proposed $3.5 billion acquisition of the Brooks and Eckerd pharmacies from Canada’s Jean Coutu Group (PJC), Inc. To remedy the alleged anticompetitive impact of the proposed...
Joint brief of the United States and the Federal Trade Commission, as amici curiae before the United States Court of Appeals for the Second Circuit, in support of plaintiffs-appellants, who were direct purchasers of the prescription brand-name drug DDAVP. Plaintiffs had brought...
Commission approval of final consent order: Following a public comment period, the Commission has approved a final consent order in the matter of Actavis Group hf. and Abrika Pharmaceuticals, Inc. The Commission vote approving issuance of the final consent order was 5-0. (FTC File No. 071-0063, the...
Testifying today on behalf of the Federal Trade Commission before the U.S. House Subcommittee on Commerce, Trade, and Consumer Protection of the Committee on Energy and Commerce regarding anticompetitive patent settlements in the U.S. pharmaceutical industry, FTC Commissioner Jon Leibowitz said...
The Commission prevented a merger-to-monopoly in the sale of generic isradipine capsules by challenging the proposed $235 million purchase of Abrika Pharmaceuticals, Inc., by the Actavis Group, an international generic pharmaceuticals company. To maintain competition in the market for...
The Federal Trade Commission today announced its challenge to the terms of Actavis Group hf.’s (Actavis) proposed acquisition of Abrika Pharmaceuticals, Inc. (Abrika), alleging that the transaction would create a monopoly in the U.S. market for generic isradipine capsules, a drug typically...
Commission approval of final consent order: Following a public comment period, the Commission has approved the issuance of final consent order in the matter concerning Johnson & Johnson’s acquisition of Pfizer, Inc.’s Consumer Healthcare business. The vote to approve the final consent order,...
The consent order settles charges that Hospira Inc.’s proposed $2 billion acquisition of rival drug manufacturer Mayne Pharma Ltd. would likely reduce competition in the following products: hydromorphone hydrochloride (hydromorphone), nalbuphine hydrochloride (nalbuphine), morphine...
To Protect Competition, Companies Must Sell Assets for Five Generic Injectable Drugs The Federal Trade Commission today announced its challenge to Hospira Inc.’s (Hospira) proposed $2 billion acquisition of rival drug manufacturer Mayne Pharma Ltd. (Mayne), along with an agreement and order...
FTC Study Shows Substantial Increase in Number of Settlements Involving a Payment to the Generic and a Restriction on Generic Entry
Shows Substantial Increase in the Number of Settlements Involving a Payment to the Generic and a Restriction on Generic Entry The Federal Trade Commission’s Bureau of Competition today issued a summary of agreements filed with the Commission in fiscal year 2006 (ending September 30, 2006) by...
The final consent order settles charges that the conduct of several organizations representing more than 2,900 independent Chicago-area physicians for agreeing to fix prices and for refusing to deal with certain health plans except on collectively determined terms. The order will...
The Federal Trade Commission today announced its decision to challenge the conduct of several organizations representing more than 2,900 independent Chicago-area physicians for agreeing to fix prices and for refusing to deal with certain health plans except on collectively determined terms. The FTC...
The Federal Trade Commission today announced its decision to challenge the terms of Johnson & Johnson’s (J&J) proposed $16.6 billion acquisition of Pfizer Inc.’s (Pfizer) Consumer Healthcare business. The FTC’s complaint alleges that the transaction as originally proposed would reduce...
The consent order settles charges that Johnson & Johnson’s (J&J) proposed $16.6 billion acquisition of Pfizer Inc.’s (Pfizer) Consumer Healthcare business would likely reduce competition in the U.S. markets for over-the-counter (OTC) H-2 blockers used to prevent and relieve...
Commission approval of final consent order: Following a public comment period, the Commission has approved the issuance of final consent order in the matter concerning Barr Pharmaceuticals, Inc.’s acquisition of PLIVA d.d. The vote to approve the final consent order, copies of which can be found on...
The Federal Trade Commission today announced its decision to challenge the terms of Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, a deal that would have led to competitive problems in the markets for 13 generic drug products. In allowing the deal to proceed...
A consent order settled charges that Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, would have likely led to competitive problems in the markets for 13 generic drug products. Watson was required to end its marketing agreements with Interpham...
U.S. District Court Judge Colleen Kollar-Kotelly yesterday entered a final order settling the Federal Trade Commission’s charges that drug company Warner Chilcott’s agreement with Barr Laboratories unlawfully delayed entry of Barr’s generic version of Warner Chilcott’s Ovcon birth control pill.

Pages